Claudio Napoli Selected Research

Diabetes Mellitus

1/2021	The human aortic endothelium undergoes dose-dependent DNA methylation in response to transient hyperglycemia.
12/2020	Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development.
5/2016	Severe Type 2 Diabetes Induces Reversible Modifications of Endothelial Progenitor Cells Which are Ameliorate by Glycemic Control.
3/2006	Glycoxidation of low-density lipoprotein promotes multiple apoptotic pathways and NFkappaB activation in human coronary cells.
12/2003	Glycoxidation of low-density lipoprotein increases TUNEL positivity and CPP32 activation in human coronary cells.
10/2002	Glycoxidized low-density lipoprotein downregulates endothelial nitricoxide synthase in human coronary cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Claudio Napoli Research Topics

Disease

41	Atherosclerosis 01/2022 - 03/2002
22	Heart Failure 02/2022 - 06/2013
19	Neoplasms (Cancer) 01/2022 - 05/2002
18	Cardiovascular Diseases (Cardiovascular Disease) 12/2023 - 05/2002
18	Inflammation (Inflammations) 01/2022 - 08/2002
13	Coronary Disease (Coronary Heart Disease) 01/2022 - 01/2004
12	Hypercholesterolemia 12/2018 - 09/2001
11	Ischemia 08/2013 - 11/2005
10	Fibrosis (Cirrhosis) 01/2022 - 04/2003
8	Type 2 Diabetes Mellitus (MODY) 02/2022 - 01/2012
8	Infections 01/2021 - 02/2008
7	COVID-19 01/2023 - 12/2020
7	Hypoxia (Hypoxemia) 05/2015 - 01/2002
7	Osteosarcoma (Osteogenic Sarcoma) 12/2013 - 10/2006
6	Diabetes Mellitus 01/2021 - 10/2002
5	Myocardial Infarction 01/2022 - 04/2015
5	Hyperglycemia 01/2022 - 04/2010
5	Hypertension (High Blood Pressure) 05/2021 - 02/2008
5	Critical Illness (Critically Ill) 12/2020 - 09/2004
4	Pulmonary Arterial Hypertension 11/2023 - 01/2021
4	Obesity 01/2023 - 01/2020
4	Cardiomyopathies (Cardiomyopathy) 12/2021 - 01/2021
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021 - 01/2004
4	Insulin Resistance 02/2020 - 01/2012
4	Atherosclerotic Plaque (Atheroma) 09/2008 - 07/2004
3	Chronic Renal Insufficiency 01/2022 - 08/2021
3	Thrombosis (Thrombus) 01/2022 - 01/2019
3	Infarction (Infarctions) 01/2022 - 02/2002
3	Cardiotoxicity 09/2021 - 02/2008
3	Dyslipidemias (Dyslipidemia) 01/2021 - 07/2011
3	Pathologic Constriction (Stenosis) 01/2020 - 08/2006
3	Neoplasm Metastasis (Metastasis) 09/2019 - 03/2008
3	Vascular Diseases (Vascular Disease) 08/2009 - 02/2003
3	Hypertrophy 04/2007 - 09/2002
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2023 - 12/2020
2	Sepsis (Septicemia) 01/2023 - 05/2014
2	Diabetic Cardiomyopathies 01/2022 - 01/2020
2	Carcinogenesis 01/2022 - 05/2007
2	Hemorrhage 01/2022 - 10/2019
2	Lung Neoplasms (Lung Cancer) 09/2021 - 01/2019
2	Left Ventricular Dysfunction 09/2021 - 01/2017

Drug/Important Bio-Agent (IBA)

23	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2008
17	AntioxidantsIBA 01/2021 - 09/2001
15	Nitric Oxide (Nitrogen Monoxide)FDA Link 05/2021 - 02/2002
12	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2006
11	Arginine (L-Arginine)FDA Link 01/2023 - 06/2004
11	CholesterolIBA 01/2022 - 03/2002
10	Glucose (Dextrose)FDA LinkGeneric 02/2022 - 04/2007
9	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2010 - 03/2002
9	oxidized low density lipoproteinIBA 07/2008 - 10/2002
8	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2023 - 11/2002
8	MicroRNAs (MicroRNA)IBA 09/2020 - 09/2012
7	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 08/2017
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2010 - 05/2004
6	SodiumIBA 02/2022 - 12/2020
6	LipidsIBA 01/2022 - 01/2002
6	erucylphosphocholineIBA 09/2019 - 02/2008
5	CytokinesIBA 01/2023 - 08/2003
5	Histones (Histone)IBA 01/2023 - 05/2015
5	NF-kappa B (NF-kB)IBA 01/2019 - 03/2002
5	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2015 - 08/2003
5	LDL Receptors (LDL Receptor)IBA 01/2012 - 03/2002
5	Lipoproteins (Lipoprotein)IBA 01/2012 - 10/2002
5	Simvastatin (Zocor)FDA LinkGeneric 12/2008 - 01/2002
5	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 03/2008 - 04/2004
4	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 12/2020
4	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 08/2013
4	Transcription Factors (Transcription Factor)IBA 10/2020 - 02/2003
4	CalciumIBA 01/2020 - 12/2003
4	RNA (Ribonucleic Acid)IBA 01/2017 - 04/2011
4	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2016 - 12/2003
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2008 - 11/2002
3	SymportersIBA 02/2022 - 08/2021
3	AntibodiesIBA 08/2017 - 06/2013
3	zofenoprilIBA 01/2017 - 12/2008
3	Mediator ComplexIBA 06/2014 - 12/2013
3	AntigensIBA 08/2013 - 09/2006
3	Nitric Oxide Synthase (NO Synthase)IBA 12/2008 - 07/2002
3	NitratesIBA 12/2008 - 01/2007
3	Ascorbic Acid (Vitamin C)FDA LinkGeneric 04/2007 - 06/2004
3	Vitamin E FDA LinkGeneric 04/2007 - 06/2004
3	Drinking WaterIBA 04/2007 - 06/2004
3	VitaminsIBA 09/2004 - 04/2004
2	Protein Isoforms (Isoforms)IBA 03/2024 - 01/2008
2	Angiotensin-Converting Enzyme 2IBA 01/2023 - 04/2009
2	Phosphotransferases (Kinase)IBA 01/2022 - 07/2008
2	AngiotensinsIBA 01/2022 - 07/2011
2	CreatinineIBA 01/2022 - 02/2014
2	MineralsIBA 01/2022 - 01/2008
2	Transaminases (Aminotransferases)IBA 10/2021 - 01/2004
2	CanagliflozinIBA 08/2021 - 08/2021

Therapy/Procedure

46	Therapeutics 12/2023 - 02/2003
8	Precision Medicine 12/2021 - 12/2019
5	Heart Transplantation (Grafting, Heart) 03/2024 - 10/2017
5	Transplantation 10/2021 - 07/2007
4	Cell- and Tissue-Based Therapy (Cell Therapy) 07/2018 - 02/2007
3	Drug Therapy (Chemotherapy) 01/2023 - 09/2012
3	Liver Transplantation 01/2022 - 08/2018
3	Glycemic Control 01/2022 - 05/2016
2	Secondary Prevention 12/2023 - 01/2021